Sacubitril / Valsartan Oral Tablet [Entresto]
Sponsors
The Young Investigator Group of Cardiovascular Research, Guangdong Provincial People's Hospital, Germans Trias i Pujol Hospital, University of Sao Paulo General Hospital, Duke University
Conditions
Acute Myocardial InfarctionChagas CardiomyopathyComplex Congenital Heart DiseaseCovid19Heart FailureHemodialysis ComplicationHypertensionObesity
Phase 1
Phase 3
Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
CompletedNCT04753112
Start: 2020-10-29End: 2021-09-20Updated: 2021-09-28
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
RecruitingNCT04853758
Start: 2021-05-06End: 2024-12-01Target: 200Updated: 2024-04-04
Unknown Phase
The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction
CompletedNCT03893435
Start: 2018-12-01End: 2022-10-01Updated: 2022-10-06
Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure
NCT04458285
Start: 2020-01-01End: 2020-12-31Target: 118Updated: 2020-10-06
Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
RecruitingNCT05498675
Start: 2021-09-01End: 2027-06-30Target: 180Updated: 2025-02-13
National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/Valsartan
NCT06149806
Start: 2021-07-01End: 2025-12-31Target: 50Updated: 2023-11-29